ADC Therapeutics disclosed top-line results from the Phase III LOTIS-5 confirmatory trial of Zynlonta (loncastuximab tesirine) plus rituximab in relapsed or refractory diffuse large B-cell lymphoma. The company reported 27 deaths in the Zynlonta arm versus nine in the control arm, raising safety concerns and weighing on investor confidence. While the company said overall survival showed no detrimental effect and it reached statistical significance on progression-free survival, the death imbalance and lack of survival benefit complicate any path to expanded positioning. The disclosure also adds uncertainty to regulators’ assessment of risk-benefit for earlier-line use. For biotech stakeholders, LOTIS-5 becomes a reference point for how confirmatory programs can undermine accelerated approval advantages if safety signals are not convincingly resolved. The market reaction in the article reflects how mortality-related findings—especially in older populations—can quickly change competitive and commercial expectations.